Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Technical Chemical & Products (TCPI) -- Ignore unavailable to you. Want to Upgrade?

To: Wesson72 who wrote (23)	11/5/1997 3:53:00 PM
From: Rob E.	Respond to of 111

Greg...thanks for the encouraging words. I agree completely...EOM

To: Wesson72 who wrote (23)	12/15/1997 11:56:00 AM
From: Wesson72	Respond to of 111

Clinical Trial Announced: Results in Q1 1998. TCPI announced a clinical trial with 3000 patients to test the TD Glucose Monitoring System. In the release that appeared in BusinessWire (http://biz.yahoo.com/bw/971215/technical_chemicals_1.html) it is stated that the glucose monitoring system market is $2-3 billion and will grow to $5 billion by the turn of the century. It is interesting to note that the NIH recommends glucose monitoring 4-6 times/day. On average diabetics test less than once a day "citing pain, inconvenience and risk of infection associated with the use of conventional finger stick blood glucose monitoring systems." I think that we all hope that the patch system will prove to be more tolerable than the finger stick method and as accurate. If this is the case than the TD Glucose Monitoring System will give us the EPS growth that we need. Greg